The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby. The FDA cleared Attruby to treat patients with the heart condition known as transthyretin ...
6don MSNOpinion
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
BridgeBio is pointing to the approved indication for Attruby as it gears up to launch the drug with a list price of $18,759 for a 28-day supply, saying it is the only drug with a label that says ...
This week, the FDA issued recommendations for streamlining the clearance process for AI-powered medical devices. The memo announcing this change recognizes that the utilization of AI in devices “is an ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...
BridgeBio’s Attruby may be even more effective. The twice a day pill regimen reduced the risk of death and recurrent cardiovascular hospitalizations by 42% after 30 months of treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback